PNC Financial Services Group
VKTX icon

PNC Financial Services Group’s Viking Therapeutics VKTX Stock Holding History

PNC Financial Services Group’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$222K Sell
5,685
-2,271
-29% -$73.4K ﹤0.01% 2389
2026
Q1 		$259K Buy
7,956
+103
+1% +$3.31K ﹤0.01% 2158
2025
Q4 		$276K Buy
7,853
+2,167
+38% +$76.8K ﹤0.01% 2059
2025
Q3 		$149K Sell
5,686
-701
-11% -$20.9K ﹤0.01% 2505
2025
Q2 		$169K Buy
6,387
+2,530
+66% +$66.6K ﹤0.01% 2322
2025
Q1 		$93.1K Buy
3,857
+1,078
+39% +$34.1K ﹤0.01% 2705
2024
Q4 		$112K Sell
2,779
-3,460
-55% -$197K ﹤0.01% 2613
2024
Q3 		$395K Buy
6,239
+1,396
+29% +$81.9K ﹤0.01% 1709
2024
Q2 		$257K Buy
4,843
+1,260
+35% +$82.6K ﹤0.01% 1975
2024
Q1 		$294K Buy
3,583
+2,578
+257% +$115K ﹤0.01% 1902
2023
Q4 		$18.7K Buy
1,005
+5
+0.5% +$65 ﹤0.01% 3468
2023
Q3 		$11.1K Sell
1,000
-669
-40% -$9.57K ﹤0.01% 3709
2023
Q2 		$27.1K Buy
1,669
+669
+67% +$14K ﹤0.01% 3402
2023
Q1 		$16.6K Hold
1,000
– – ﹤0.01% 3580
2022
Q4 		$9.4K Hold
1,000
– – ﹤0.01% 3797
2022
Q3 		$3K Sell
1,000
-1,978
-66% -$6.48K ﹤0.01% 4118
2022
Q2 		$9K Buy
2,978
+1,978
+198% +$4.89K ﹤0.01% 3853
2022
Q1 		$3K Hold
1,000
– – ﹤0.01% 4132
2021
Q4 		$5K Sell
1,000
-1,000
-50% -$5.61K ﹤0.01% 3990
2021
Q3 		$13K Hold
2,000
– – ﹤0.01% 3678
2021
Q2 		$12K Buy
2,000
+500
+33% +$2.97K ﹤0.01% 3653
2021
Q1 		$9K Buy
1,500
+500
+50% +$3.52K ﹤0.01% 3687
2020
Q4 		$6K Sell
1,000
-4,500
-82% -$27.3K ﹤0.01% 3690
2020
Q3 		$32K Buy
5,500
+4,500
+450% +$31K ﹤0.01% 2994
2020
Q2 		$7K Hold
1,000
– – ﹤0.01% 3571
2020
Q1 		$5K Sell
1,000
-550
-35% -$3.38K ﹤0.01% 3612
2019
Q4 		$12K Hold
1,550
– – ﹤0.01% 3475
2019
Q3 		$11K Hold
1,550
– – ﹤0.01% 3534
2019
Q2 		$13K Hold
1,550
– – ﹤0.01% 3502
2019
Q1 		$15K Buy
1,550
+1,250
+417% +$10.5K ﹤0.01% 3475
2018
Q4 		$2K Hold
300
– – ﹤0.01% 3879
2018
Q3 		$5K Buy
+300
New +$3.57K ﹤0.01% 3830

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

PNC Financial Services Group's VKTX Position: Q2 2026 in Review

PNC Financial Services Group reduced its Viking Therapeutics (VKTX) stake by 29% in Q2 2026, selling an estimated $73.4K and leaving 5,685 shares worth $222K. The position accounts for ﹤0.01% of the portfolio, ranked #2389.

PNC Financial Services Group first reported a position in VKTX in Q3 2018 and has held it in 32 quarters since. The position peaked at $395K in Q3 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • PNC Financial Services Group held 5,685 shares of Viking Therapeutics worth $222K as of Q2 2026.
  • PNC Financial Services Group sold 2,271 Viking Therapeutics shares in Q2 2026, an estimated $73.4K.
  • Viking Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #2389 holding.
  • PNC Financial Services Group first reported a position in Viking Therapeutics in Q3 2018 and has held it in 32 quarters since.
  • PNC Financial Services Group's Viking Therapeutics position peaked at $395K in Q3 2024.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.